pregnant.baby_.hands_.jpg
24 January 2023

Variable Pregnancy Outcomes with Belimumab in SLE

An analysis of the belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing/spontaneous reports looked at outcomes in pregnant systemic lupus erythematosus (SLE) exposed to belimumab reported there are few pregnancies and confounding disease and comorbidity factors to provide clear guidance for such patients. 

A total of 319 BEL-exposed pregnancies with known outcomes (excluding elective terminations) were included. They identified: 

Korean study of 439 RA pts starting JAKi, TNFi or non-TNFi. Physician choice of JAKi was more likely with age (OR 1.03)

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Korean study of 439 RA pts starting JAKi, TNFi or non-TNFi. Physician choice of JAKi was more likely with age (OR 1.03), no pulmonary Dz (OR 0.07), Higher Dz activity (OR 1.80) & prior tacrolimus (OR 2.05) https://t.co/9Vv5XfzfrH https://t.co/59Whi7tCIE
Links
https://bit.ly/3ZShLEH

JAMA: 13 million In US have latent TB (5-10% risk of getting active TB). Review of LTBI regimens: - Preferred: 4 mos Ri

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
JAMA: 13 million In US have latent TB (5-10% risk of getting active TB). Review of LTBI regimens: - Preferred: 4 mos Rifampin: better/safer of INH - Preferred: 3 mos of INH + rifapentine - more completers less SAE - ALternative: 6-9 mos of INH https://t.co/vZTmSKTFWu https://t.co/W7BraJs6yC
Links
https://bit.ly/3wkpAp3
23 January 2023
Periprosthetic Joint Infections
Recent NEJM has reviewed arthroplasty-associated infection and periprosthetic joint infections (PJI), noting this is a rare event; notably these infections are caused by skin microorganisms introduced during arthroplasty surgery or may be seeded post-surgically, via hematogenously spread or compromised local tissues (skin or bone).
23 January 2023
JAK-pot Study: To Cycle or Switch after JAK inhibitor Failure?

Data from 17 international registries (JAK-pot collaboration) suggest that for Rheumatoid arthritis (RA) patients failing their first janus kinase inhibitor (JAKi), it did not matter if they were cycled to another JAKi or switched to a biologic disease-modifying antirheumatic drug (bDMARD).

AS, but not PsA, has Increased Mortality Risk A recent meta-analysis showed a significantly increased risk of overall

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
AS, but not PsA, has Increased Mortality Risk A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA), largely associated with cardiovascular-specific mortality. https://t.co/gnd0bMQIui https://t.co/sWFhJAIaGH
Links
https://bit.ly/3kvfQps

Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interle

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. https://t.co/pdfxa3u29k https://t.co/0wLl48Fvj6
Links
https://bit.ly/3Xt9O78

PRedSS was a small trial of 35 pts with early diffuss systemic sclerosis Rx w/ prednisolone(17) vs placebo(18). At 3 mos

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
PRedSS was a small trial of 35 pts with early diffuss systemic sclerosis Rx w/ prednisolone(17) vs placebo(18). At 3 mos outcomes favored Pred, but nonsignificant (HAQ-DI -0.10; p= 0.25 & mRSS -3.90; p= 0.07), but less pain & anxiety https://t.co/iZw2L9SLhF https://t.co/2G2MuVMUSJ
Links
https://bit.ly/3HluhVY
23 January 2023
Burden of BMI on Costs of Musculoskeletal Diseases

A cross-sectional global study shows a substantial impact of obesity and BMI on the health and economic impact of patients with musculoskeletal (MSK) disorders.

In this cross-sectional study of 192 countries and territories, 7.3 million years lived with disability and $180.7 billion total costs associated with musculoskeletal disorders were attributable to high BMI. The disease and economic burden varied by region and country.

Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×